IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare

IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare

U.S.-based cancer testing startup Grail Inc has filed for a U.S. initial public offering (IPO) to complete the commercialization of its population-scale multi-cancer early detection testing capability based on a technology called liquid biopsy. Grail was spun out of gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures … Read more

Categories IPO

In Conversation: Dr. Nina Pollak’s Vision For A Cleaner Environment Using Synthetic Biology

In Conversation: Dr. Nina Pollak’s Vision For A Cleaner Environment Using Synthetic Biology

I interviewed Dr Nina Pollak via Zoom to discuss her research interests and career aspirations. She is presently a CSIRO Synthetic Biology Future Science Fellow at the Molecular Engineering Group led by A/Prof Macdonald at the University of the Sunshine Coast in Australia. Originally from Austria, Dr. Pollak has completed a number of international research projects … Read more

How China’s Immense Data Resources Will Impact The Future Of Life Sciences

How China’s Immense Data Resources Will Impact The Future Of Life Sciences

China is slowly tightening its grip on one of its most valuable resources: health data. On July 3, China’s National People’s Congress of China published a draft Data Security Law, that represents a shift in the country’s data strategy. According to the National Information Center, China will pursue “asymmetric advantages in this new round of … Read more

Why The U.S. Will Be Forced To Remove China From Its Domestic Bio-Tech Stack

Why The U.S. Will Be Forced To Remove China From Its Domestic Bio-Tech Stack

Recent face offs at the Sino-Indian border are part of a long-term, low-grade military conflict over a border dispute. What’s different this time is India’s response. Rather than escalate militarily, the Indian government chose to express its sovereignty by banning Chinese apps from India. This is an economic response, and one remedy that is not … Read more

IPO: Freeline Therapeutics Plans To Capitalize On Liver-directed Gene Therapies

IPO: Freeline Therapeutics Plans To Capitalize On Liver-directed Gene Therapies

Freeline Therapeutics is a UK-based biotechnology company that develops liver-directed gene therapies for bleeding disorders and other diseases. Its therapies are based on a next-generation proprietary AAV vector platform, specifically a gene therapy to treat haemophilia B. The company plans to raise $125 million by offering 7.4 million ADSs at a price range of $16 … Read more

Categories IPO

A Look At China’s National Innovation Strategy In Relation To The Biotechnology Sector

A Look At China’s National Innovation Strategy In Relation To The Biotechnology Sector

According to a report by the World Bank, China is well advanced in building a national innovation system (NIS) capable of supplying the innovation and technologies needed for a growing economy that is productivity-led. Currently, the country’s NIS focuses on discovering new innovations and accelerating the diffusion of technologies throughout to support a rapidly increasing … Read more

Chinese Biotech BeiGene Raises Largest-Ever Follow-On Offering

Chinese Biotech BeiGene Raises Largest-Ever Follow-On Offering

BeiGene was founded nearly ten years ago in China. Today, the company a lot more than a cute-sounding name. It is a commercial-stage, publicly-traded biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The Chinese biotech giant raised $2 billion in a registered direct offering in July. … Read more